Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes Plc (NQ: ALKS )

28.35 +0.52 (+1.87%)
Streaming Delayed Price Updated: 2:58 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes Plc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark
Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84. 
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential. 
Via InvestorPlace
Alkermes Stock Gets RS Rating Upgrade; Profits Surge
In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday. 
Via Investor's Business Daily
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Alkermes's Earnings Outlook
Via Benzinga
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Is NASDAQ:ALKS suited for growth investing?
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
NASDAQ:ALKS, an undervalued stock with good fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS).
High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this. 
Via Chartmill
NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Madrigal Pharmaceuticals Stock Shows Rising Relative Strength
A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
3 Top Pharma Stocks to Buy Now: February 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth. 
Via InvestorPlace
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
NASDAQ:ALKS, a growth stock which is not overvalued.
Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS. 
Via Chartmill
Decoding 5 Analyst Evaluations For Alkermes
Via Benzinga
Delving into NASDAQ:ALKS's Growth Prospects.
High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this. 
Via Chartmill
Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating
Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Cassava Sciences Stock Continues Showing Rising Relative Strength
Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. 
Via Investor's Business Daily
The 3 Most Undervalued Biotech Stocks to Buy in January
These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios. 
Via InvestorPlace
For those who appreciate value investing, NASDAQ:ALKS is a compelling option with its solid fundamentals.
Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS). 
Via Chartmill
When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
ALKERMES PLC (NASDAQ:ALKS) showing high EPS and FCF growth while beating expectations
Why the growth investor may take a look at NASDAQ:ALKS. 
Via Chartmill
Where Alkermes Stands With Analysts
Via Benzinga
Uber Will Join The S&P 500 Index. The Stock Is Jumping.
The ride-hailing giant will join the index as part of a quarterly rebalancing. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering.
Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS. 
Via Chartmill
Why Is Mural Oncology (MURA) Stock Up 59% Today?
Mural Oncology stock is climbing higher on Friday as the company's shares bounce back from a dip yesterday during its public debut. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.